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performed. Under fluoroscopy, nab-rapamycin (Abraxis Bioscience) (5 or 500 μg) or
vehicle was delivered to the adventitia using a micro-infusion catheter (Mercator
MedSystems). After 28 days,the arteries were harvested. The primary outcome was
histomorphometric evidence of luminal stenosis and remodeling. Vessel injury was
scored on a validated ordinal scale.
Results: There was 100% procedural success in 16 injury sites treated with adventitial
injections. Nab-rapamycin treated vessels had significantly larger lumen (p=0.01,
ANOVA) and total vessel areas (p=0.005) indicating less negative remodeling. Percent
luminal stenosis and maximal intimal width decreased in a dose-dependent fashion.
Control vessels had significantly more fibrosis (p<0.001).
Mean values for measured and calculated metrics for 16 injured femoral
segments treated with adventitial injection of vehicle or nab-rapamycin
*p-values based on ANOVA
Conclusion: These data suggest that adventitial delivery of rapamycin decreases
luminal stenosis by inhibiting IH and preventing negative remodeling. The decreased
fibrosis in treated vessels suggests a mechanism by which rapamycin may affect vessel
remodeling following injury.
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Background: Mesenchymal precursor cells (MPC) are cells that exerted therapeutic
actions in pre-clinical models of acute myocardial infarction (AMI). They are immune
privileged and can be given in an allogeneic setting. The aim of the current large animal
study was to assess the effect of intracoronary delivery of allogeneic MPC directly
following an AMI.
Methods: The 30 sheep that survived the anterior AMI were blindly randomized to
receive IC infusion of either saline (n=10) or three incremental doses of allogeneic
MPC (n=20). Cardiac function was assessed using echocardiography. After 8 weeks,
sheep were sacrificed and the hearts excised for morphometric and histological
analysis.
Results: In the control group, global LVEF deteriorated to 36.6±2.0%, whereas it was
enhanced in treated sheep to 45.4±1.4% (p= 0.009). Also regional function improved,
as fractional area change (FAC) in the apex increased by 39% in MPC-treated animals
compared to controls (p=0.027), and FAC in the mid-ventricle increased by 30%
(p=0.007). Local systolic wall thickening in the affected antero-septal wall improved
from 9.6±5.5% in controls to 39.1±1.8% in treated animals (p< 0.001) and in the
anterior wall from 13.8± 3.6% to 34.7±1.9% (p<0.001). Morphometric analysis
revealed that MPC treatment resulted in a 40% reduction in infarct size from
18.2±1.7% in control animals to only 10.9±0.6% in treated sheep (p<0.001). Also,
infarct (p<0.001) and border zone (p=0.011) thickness were enhanced in the treatment
group. Histological analysis showed an increase in blood vessel density of >50% in
the infarct (p<0.001), remote (p=0.007) and border (p<0.001) areas evoked by MPC
therapy. In addition, cardiomyocyte size was smaller in border (p<0.001) and remote
(p=0.002) areas, accompanied by reduced collagen contents, suggestive of decreased
remodeling.
Conclusion: Intracoronary delivery of allogeneic MPC directly after the AMI resulted
in preserved global and regional cardiac function, evoked by reduced infarct size,
increased perfusion and reduced remodeling.
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Background: Renal sympathetic nerve hyperactivity contributes to resistant
hypertension. Recent innovation with catheter-based ablation of renal nerves has shown
efficacy in reducing blood pressure without procedural mortality. We hypothesize that
pharmacologic sympathectomy with guanethidine monosulfate (GNT) delivered to
renal peri-adventitial tissue would produce sustained renal artery denervation.
Methods: A micro-infusion catheter (Bullfrog®, Mercator MedSystems, Inc.) was
introduced via femoral artery into renal arteries of (N=15) swine. GNT (50 mg/6 ml,
N=12) or vehicle (6 ml, N=3) was infused to the peri-adventitia of each renal artery
under fluoroscopic guidance. Subjects were divided between a pharmacokinetic (PK)
experiment with 3 treated subjects each sacrificed at 1, 7 or 28 days, and a histology
experiment with 3 treated and 3 control subjects sacrificed at 28 days. The primary
efficacy endpoint for both experiments was kidney NE tissue content. Secondary
outcomes were plasma and tissue GNT levels, histological evidence of renal artery
denervation and renal artery injury.
Results: The 24 treated and 6 control renal arteries had 100% procedural success in
the delivery of GNT or vehicle. Histology showed optimal healing in injected renal
arteries: complete endothelialization, no thrombus formation, no or minimal non-
stenosing neointima and no or minimal medial fibrosis, with no difference between
treated and control arteries (p=NS). There was a time-dependent decrease in renal NE
content, dropping 20±16% (p=NS) by 7 days and 58±10% (p<0.024) at 28 days, each
compared to vehicle controls at 28 days. Denervation was evident from NE drops and
from histology, with reduced fiber density and endo- and peri-neurial fibrosis in GNT-
injected animals, but no neuronal changes evident in vehicle controls. PK analysis
revealed GNT retention of 54 ng/g around the renal arteries at 28 days. By contrast,
GNT plasma concentrations were below adrenergic blocking levels at 24 hours post-
injection.
Conclusion: GNT, delivered to the renal peri-adventitia resulted in a time-dependent
reduction in kidney NE content and specific immune-mediated destruction of renal
artery perivascular nerve tissue. Peri-adventitial drug delivery appears to be a safe and
efficient modality to maximize tissue concentration while minimizing plasma spillover.
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Background: The influence of intracoronary abciximab and bivalirudin as an
anticoagulant in ST elevation mycoardial infarction (STEMI) on myocardial salvage
and reperfusion injury (RI) is undetermined
Methods: In 23 landrace pigs STEMI was induced by the occlusion of over – the –
wire (OTW) balloon catheter in the medial left anterior descending artery for 60
minutes. In all animals bivalirudin was administred intravenously. Minutes prior to
reperfusion animals were randomized into the study group (n=11) in which 0,4 mg/kg
downstream i.c. abciximab through the central lumen of the OTW was infused, or to
the control group (n=12), in which 5 ml placebo (0,9% NaCl) was adiministred in the
same way. The control coronary angiography and ventriculography was performed
before ischaemia, 30 minutes and 48 hours after reperfusion. The animals were
sacrificed 2 days after the procedure. The infarct area (IA) and area at risk (AAR) were
marked with tetrazolinum and Evans blue respectively. The primary endpoint was the
percentage of IA in the AAR (IA/AAR%) and the left ventricle (IA/LV%).
Results: The animals in both groups were comparable with regard to sex and weight.
Hearts in the both groups had similar AAR (41,9% vs. 40,5%; p=0,7). The average
infarct size was comparable in the control and the study group as expressed by
IA/AAR% (58,1% vs 57,3%; p=0,8) and IA/LV% (28,5% vs. 26,3% p=0,5). This
corresponded well with peak troponin level (138,8 mg/ml vs. 129,8 mg/ml; p=0,59)
and hsCRP concentration (7822,5 ng/ml vs 8806,5 ng/ml; p=0,38). Furthermore the
left ventricle ejection fraction after 48 hours was also equivalent (32,2 % vs 36,5%;
p=0,21), although the decrease from baseline at 48 hours was significantly lower in
the study group (20.5 vs 29.5%, p=0.02) The enhancement of apoptosis in the AAR
was similar in both groups (16,2 vs. 15,1; p=0,07).The number of hemorrhagic
infarctions confirmed by micro and macroscopic evaluation was higher in the study
group (70% vs. 20%, p=0,05)
Conclusion: Intracoronary abciximiab with peripheral bivalirudin is not superior to
bivalirudin unaided in myocardial salvage caused by reperfusion injury in the model
of porcine ischemia/reperfusion model. This could be caused by higher number of
hemorrhagic infarcts caused by abciximab
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Background: Preclinical safety and pharmacokinetics of the NEVO™ stent, a novel
sirolimus-eluting stent (SES) that uses bioresorbable PLGA and reservoirs (RES
TECHNOLOGY™, Cordis Corporation, NJ), have been evaluated on single stent
implants. As patients often receive multiple single or overlapping (OL) stents, we
examined the influence of overlap and sirolimus dose on the systemic and local tissue
pharmacokinetics of NEVO™ stents.
Methods: Single and OL NEVO™ stents, and OL double dose (2x) NEVO™ stents
(2.5x12 mm) were implanted in non-diseased porcine coronary arteries (n=6–
9/cohort/time point; 100% OL) for 1, 3, 8, 14, 30, or 60 days. Harvested stents, arteries,
myocardium, lung, liver, kidney, and blood (4 hours, 1, 2, 3, 5, 8, 14, 30, and 60 days
post-implant) were analyzed for sirolimus content. Abnormal tissues were evaluated
for histopathology.
Results: There were no early deaths or adverse clinical effects from OL 2x-NEVO™
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